461 related articles for article (PubMed ID: 11722289)
1. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
3. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
4. Functional interaction of intestinal CYP3A4 and P-glycoprotein.
Kivistö KT; Niemi M; Fromm MF
Fundam Clin Pharmacol; 2004 Dec; 18(6):621-6. PubMed ID: 15548232
[TBL] [Abstract][Full Text] [Related]
5. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
Ito K; Kusuhara H; Sugiyama Y
Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
[TBL] [Abstract][Full Text] [Related]
6. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
Zhang Y; Benet LZ
Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
[TBL] [Abstract][Full Text] [Related]
7. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
8. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
9. The drug efflux-metabolism alliance: biochemical aspects.
Benet LZ; Cummins CL
Adv Drug Deliv Rev; 2001 Oct; 50 Suppl 1():S3-11. PubMed ID: 11576692
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
von Richter O; Burk O; Fromm MF; Thon KP; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2004 Mar; 75(3):172-83. PubMed ID: 15001968
[TBL] [Abstract][Full Text] [Related]
11. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
12. Active secretion and enterocytic drug metabolism barriers to drug absorption.
Wacher VJ; Salphati L; Benet LZ
Adv Drug Deliv Rev; 2001 Mar; 46(1-3):89-102. PubMed ID: 11259835
[TBL] [Abstract][Full Text] [Related]
13. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.
Benet LZ; Cummins CL; Wu CY
Int J Pharm; 2004 Jun; 277(1-2):3-9. PubMed ID: 15158963
[TBL] [Abstract][Full Text] [Related]
14. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
15. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study.
Watanabe T; Maeda K; Nakai C; Sugiyama Y
J Pharm Sci; 2013 Sep; 102(9):3196-204. PubMed ID: 23754337
[TBL] [Abstract][Full Text] [Related]
17. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine.
Suzuki H; Sugiyama Y
Eur J Pharm Sci; 2000 Nov; 12(1):3-12. PubMed ID: 11121729
[TBL] [Abstract][Full Text] [Related]
18. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
[TBL] [Abstract][Full Text] [Related]
19. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
20. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.
Mudra DR; Desino KE; Desai PV
Curr Drug Metab; 2011 Oct; 12(8):750-73. PubMed ID: 21568936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]